LAUSR

Originally received: March 28, 2017. Final revision: July 21, 2017. Accepted: August 30, 2017. Available online: October 27, 2017. Manuscript no. 2017-714. 1 Department of Ophthalmology, University of Bonn, Bonn, Germany. 2 Department of Ophthalmology and Westmead Institute for Medical Research, University of Sydney, Sydney, Australia. 3 Vitreous Retina Macula Consultants of New York, New York, New York. 4 Department of Ophthalmology, New York University School of Medicine, New York, New York. 5 Doheny Eye Institute, Los Angeles, California. 6 University of California at Los Angeles, Los Angeles, California. 7 F. Hoffmann-La Roche Ltd., Basel, Switzerland. 8 Genentech, Inc., South San Francisco, California. Financial Disclosure(s): The author(s) have made the following disclosure(s): M.F.: Personal fees Bayer, Heidelberg Engineering, Novartis, Genentech/Roche; Patent US20140303013 A1 pending; Research grant German Research Foundation (DFG): FL 658/4-1 and FL 658/4-2. P.M.: Consultant Abbott, Allergan, Bayer, Novartis, Roche. K.B.F.: Consultant Genentech, Optos, Optovue, Heidelberg Engineering, Bayer HealthCare. F.G.H.: Consulting fees Acucela, Allergan, Bayer, GSK, Heidelberg Engineering, Novartis, Genentech/Roche. S.S.: Consultant Genentech, Inc., Allergan, Alcon, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Carl Zeiss Meditec, Inc., Optos plc; Research support Genentech, Inc., Allergan, Carl Zeiss Meditec, Inc., Optos plc. C.B., E.C.H., and D.F.: Employees Genentech, Inc. D.F.: Stock/stock options F. Hoffmann-La Roche Ltd.